{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T14:03:23Z","timestamp":1698501803948},"reference-count":17,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":4771,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[1996,4]]},"abstract":"<jats:p><jats:bold>Zusammenfassung. <\/jats:bold> Aus der Hefepilzkolonisation des Darmtraktes ergeben sich f\u00fcr die therapeutische und prophylaktische Anwendung von Polyenantimykotika (Nystatin, Amphotericin B) unterschiedliche Konsequenzen: Abwehrgesch\u00e4digten, neutropenischen Patienten sollten sie langfristig w\u00e4hrend erh\u00f6hter Mykoserisiken verabreicht werden. Die Dosierung richtet sich nach dem Alter, der Funktionst\u00fcchtigkeit des Gastrointestinaltraktes und dem Grundleiden des Patienten. Beim abwehrkompetenten Menschen sollte dagegen die kommensale Hefepilzfiora nicht ohne klinische Indikation medikament\u00f6s unterdr\u00fcckt werden, da eine dauerhafte Eradikation von Hefen im Darmtrakt nicht m\u00f6glich ist. Die Pilze treten \u2014 wenn auch zun\u00e4chst in geringer Menge \u2014 etwa 5\u201314 Tage nach Therapieende erneut in den Faeces auf. Der Einflu\u00df oral applizierter Polyenantimykotika l\u00e4\u00dft sich im Darmlumen nach kurzer Zeit beobachten. Nystatin\u2010 und Amphotericin\u2010B\u2010Spiegel liegen ab 2., sp\u00e4testens 3. Tag kontinuierlich w\u00e4hrend der Verabreichung und maximal 10 Tage nach Therapieende in effektiven Konzentrationen im Stuhl vor. Parallel dazu ist das Vorkommen von Hefen in den Faeces deutlich vermindert oder unter die Nachweisgrenze von Pilzkulturen gesunken. Eine langfristige orale Anwendung von Polyenantimykotika bei unklaren klinischen Beschwerden abwehrkompetenter Patienten ohne massiven intestinalen Hefepilzbefall ist nicht gerechtfertigt.<\/jats:p><jats:p><jats:bold>Summary. <\/jats:bold> On the basis of intestinal yeast colonization different consequences for therapeutic and prophylactic administration of polyene antimycotics have to be drawn. Immunocompromised neutropenic patients should orally receive polyene antifungal drugs (nystatin or amphotericin B) for a long time during the period of increased risk for systemic candidosis. The level of daily dosing is dependent on age, physiological status of the gastrointestinal tract, and underlying disease of the patient. In immunocompetent persons the normal commensal yeast flora should not be suppressed by antifungal chemoprophylaxis if no clinical indications are present, because permanent eradication of yeast in the intestinal tract ist not attainable. About 5 to 15 days after finishing the administration of polyene antimycotics the fungi are detectable again in the faeces in low quantities. The influence of orally administered polyene drugs in the intestinal tract may be detected shortly after starting the application. Thus efficient concentrations of nystatin and amphotericin B are continuously present in the faeces 24 to 48 hours after beginning until 2 to 10 days after finishing the administration. During this time the quantity of yeast in the faeces is evidently reduced or not longer detectable by fungal culture. The oral administration of polyene antimycotics for a long<\/jats:p>","DOI":"10.1111\/j.1439-0507.1996.tb00501.x","type":"journal-article","created":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T16:37:15Z","timestamp":1240591035000},"page":"33-39","source":"Crossref","is-referenced-by-count":11,"title":["Einflu\u00df oral verabreichter Polyenantimykotika auf die Hefepilzbesiedlung des Darmtraktes: M\u00f6glichkeiten und Grenzen"],"prefix":"10.1111","volume":"39","author":[{"given":"Renate","family":"Blaschke\u2010Hellmessen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Buchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schwarze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"92","article-title":"Mykologische \u00dcberwachung von Risikoneugeborenen w\u00e4hrend der prophylaktischen Verabreichung von Nystatin","volume":"139","author":"Blaschke\u2010Hellmessen R.","year":"1991","journal-title":"Monatsschr. Kinderheilk"},{"key":"e_1_2_1_3_2","first-page":"89","article-title":"Zur intestinalen Ausscheidung von Nystatin w\u00e4hrend und nach oraler Applikation bei Risikoneugeborenen","volume":"139","author":"Blaschke\u2010Hellmessen R.","year":"1991","journal-title":"Monatschr. Kinderheilk."},{"issue":"1","key":"e_1_2_1_4_2","first-page":"84","article-title":"Amphotericin\u2010B\u2010Spiegel in Faeces und Serum w\u00e4hrend oraler Verabreichung bei Risikoneugeborenen","volume":"37","author":"Blaschke\u2010Hellmessen R.","year":"1994","journal-title":"Mycoses"},{"key":"e_1_2_1_5_2","first-page":"220","article-title":"Intestinale Ausscheidung von Nystatin w\u00e4hrend der prophylaktischen oralen Applikation bei verschiedenen Patientengruppen","volume":"21","author":"Blaschke\u2010Hellmessen R.","year":"1995","journal-title":"Mikro\u00f6kologie und Therapie"},{"key":"e_1_2_1_6_2","unstructured":"Buchmann H.(1993)Untersuchungen zur Prophylaxe systemischerCandida\u2010Mykosen: Nachweis von Amphotericin B in Faeces und Serum w\u00e4hrend und nach oraler Applikation. Dissertation A Medizinische Akademie Dresden."},{"key":"e_1_2_1_7_2","first-page":"135","article-title":"Untersuchungen zur Soorprophylaxe Neugeborener, II. Mitt.: Wirksamkeit einer generellen Fungicidin\u2010Prophylaxe bei Fr\u00fchgeborenen und hypotrophen Neugeborenen auf einer Intensivstation","volume":"47","author":"Schwarze R.","year":"1979","journal-title":"Kinder\u00e4rztl. Praxis"},{"key":"e_1_2_1_8_2","unstructured":"Pannwitz U.(1988)Mikrobiologischer Nachweis von Nystatin im Stuhl von Risikoneugeborenen nach oraler Applikation. Diplomarbeit. Medizinische Akademie Dresden."},{"key":"e_1_2_1_9_2","first-page":"162","article-title":"Besonderheiten von Pilz\u2010Keimtr\u00e4gern als Dauerausscheider","volume":"194","author":"M\u00fcller J.","year":"1993","journal-title":"Zbl. Hyg."},{"key":"e_1_2_1_10_2","unstructured":"Schwarze U.(1991)Inaktivierung von Nystatin im Magen\u2010Darm\u2010Trakt und intestinale Ausscheidung von Nystatin w\u00e4hrend prophylaktischer oraler Applikation bei verschiedenen Patientengruppen. Dissertation A Medizinische Akademie Dresden."},{"key":"e_1_2_1_11_2","first-page":"149","article-title":"Untersuchungen zur Inaktivierung von Nystatin durch Magensaft und Facces","volume":"21","author":"Schwarze U.","year":"1995","journal-title":"Mikro\u00f6kologie und Therapie"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01640934"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01666915"},{"key":"e_1_2_1_14_2","unstructured":"Schwarze U.(1989)Optimierung und Erprobung eines Bioassays zum Nachweis von Nystatin im Stuhl bei oraler Applikation. Diplomarbeit Medizinische Akademie Dresden."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.1990.33.3.129"},{"issue":"1","key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/myc.1990.33.1s.42","article-title":"Vergleich von oraler Fluconazol\u2010 und Amphotericin\u2010B\u2010Prophylaxe gegen Pilzinfektionen in der Neutropenie\u2010Phase antileuk\u00e4misch behandelter Patienten","volume":"33","author":"Finke R.","year":"1990","journal-title":"Mycoses"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1070328"},{"key":"e_1_2_1_18_2","volume-title":"Candida and Candidosis. A review and bibliography","author":"Odds F. C.","year":"1988"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.1996.tb00501.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.1996.tb00501.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T12:26:53Z","timestamp":1695817613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.1996.tb00501.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,4]]},"references-count":17,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[1996,4]]}},"alternative-id":["10.1111\/j.1439-0507.1996.tb00501.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.1996.tb00501.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,4]]}}}